New Strategies in Prostate Cancer: Prostate-Specific Membrane Antigen (PSMA) Ligands for Diagnosis and Therapy

Key issues for prostate cancer patients are the detection of recurrent disease and the treatment of metastasized cancer. Early detection is a major challenge for all conventional imaging modalities. Furthermore, therapy of patients with hormone-resistant tumor lesions presents a major clinical chall...

Full description

Saved in:
Bibliographic Details
Published in:Clinical cancer research 2016-01, Vol.22 (1), p.9-15
Main Authors: Haberkorn, Uwe, Eder, Matthias, Kopka, Klaus, Babich, John W, Eisenhut, Michael
Format: Article
Language:English
Subjects:
Antigens, Surface - metabolism
Biomarkers
Combined Modality Therapy
Glutamate Carboxypeptidase II - metabolism
Humans
Ligands
Male
Molecular Targeted Therapy
Positron-Emission Tomography
Prostatic Neoplasms - diagnosis
Prostatic Neoplasms - metabolism
Prostatic Neoplasms - therapy
Prostatic Neoplasms, Castration-Resistant - diagnosis
Prostatic Neoplasms, Castration-Resistant - metabolism
Prostatic Neoplasms, Castration-Resistant - therapy
Radioimmunotherapy
Radiopharmaceuticals
Tomography, Emission-Computed, Single-Photon
Tomography, X-Ray Computed
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Key issues for prostate cancer patients are the detection of recurrent disease and the treatment of metastasized cancer. Early detection is a major challenge for all conventional imaging modalities. Furthermore, therapy of patients with hormone-resistant tumor lesions presents a major clinical challenge. Because the prostate-specific membrane antigen (PSMA) is frequently overexpressed in prostate cancer, several PSMA-targeting molecules are under development to detect and treat metastatic castration-resistant prostate cancer (mCRPC). mCRPC represents a situation where cure is no longer achievable and novel therapeutic approaches for palliation and increase of survival are needed. In this article, we discuss the recent development for noninvasive detection of recurrent disease and therapy of mCRPC with corresponding PSMA-targeted radioligands.
ISSN:1078-0432
1557-3265
DOI:10.1158/1078-0432.CCR-15-0820